Bioxytran Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Selling, General & Admin	1.39	2.11	2.65	1.16	2.2	Upgrade
Research & Development	0.45	0.11	1.15	0.98	2.01	Upgrade
Amortization of Goodwill & Intangibles	0.01	0.01	0.01	0	-	Upgrade
Operating Expenses	1.85	2.23	3.81	2.14	4.21	Upgrade
Operating Income	-1.85	-2.23	-3.81	-2.14	-4.21	Upgrade
Interest Expense	-0.19	-0.77	-0.75	-0.52	-0.31	Upgrade
Other Non Operating Income (Expenses)	-0.22	0.13	-	-	-	Upgrade
EBT Excluding Unusual Items	-2.26	-2.87	-4.56	-2.66	-4.53	Upgrade
Other Unusual Items	0.13	0.49	-	-	-	Upgrade
Pretax Income	-2.12	-2.38	-4.56	-2.66	-4.53	Upgrade
Earnings From Continuing Operations	-2.12	-2.38	-4.56	-2.66	-4.53	Upgrade
Minority Interest in Earnings	-	0.01	0.09	0.19	0.5	Upgrade
Net Income	-2.12	-2.37	-4.47	-2.46	-4.03	Upgrade
Net Income to Common	-2.12	-2.37	-4.47	-2.46	-4.03	Upgrade
Shares Outstanding (Basic)	92	139	134	115	106	Upgrade
Shares Outstanding (Diluted)	92	139	134	115	106	Upgrade
Shares Change (YoY)	-33.73%	3.45%	16.13%	8.57%	13.07%	Upgrade
EPS (Basic)	-0.02	-0.02	-0.03	-0.02	-0.04	Upgrade
EPS (Diluted)	-0.02	-0.02	-0.03	-0.02	-0.04	Upgrade
EBITDA	-1.84	-2.22	-3.8	-2.13	-	Upgrade
D&A For EBITDA	0.01	0.01	0.01	0	-	Upgrade
EBIT	-1.85	-2.23	-3.81	-2.14	-4.21	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.